证券代码：002622 证券简称：皓宸医疗 公告编号：2025-006 皓宸医疗科技股份有限公司 关于 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第五届董事会第十四次会议及第五届监事会第十四次会议，审议通过了《关于< 公司 2024 年度利润分配预案>的议案》。根据《公司法》及《公司章程》等有关 规定，该事项需提交股东大会审议。现将具体情况公告如下： 一、公司 2024 年度利润分配预案 根据众华会计师事务所（特殊普通合伙）出具的公司 2024 年度审计报告， 截至 2024 年 12 月 31 日，公司合并财务报表未分配利润余额为-455,808,714.88 元，母公司财务报表未分配利润余额为-371,184,054.27 元。公司 2024 年度实 现归属于上市公司股东的净利润为-37,690,897.81 元，母公司实现净利润为- 40,345,955.75 元。 经公司第五届董事会第十四次会议审议通过，公司拟定 2024 ...

三、分红送配方案情况 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 29860.41万股，累计占流通股比： 35.54%，较上期变化： 570.00万股。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 广州汇垠日丰投资合伙企业(有限合伙) | 20000.00 | 23.81 | 不变 | | 陕西省国际信托股份有限公司-陕国投·鑫鑫向荣78号证券 | | | | | 投资集合资金信托计划 | 3226.32 | 3.84 | 不变 | | 青岛鑫汇合投资管理有限公司 | 1506.10 | 1.79 | 不变 | | 王存斌 | 1385.91 | 1.65 | 不变 | | 徐宝春 | 905.83 | 1.08 | -159.86 | | 中信证券股份有限公司 | 808.08 | 0.96 | 新进 | | 上海清淙投资管理有限公司-清淙睿智一号私募证券投资基 | | | | | 金 | 600.00 | 0.71 | 新进 | | 郏森茂 | 520.34 | 0.62 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan, representing a year-over-year growth of 15%[15]. - The company's operating revenue for 2024 was ¥861,568,412.49, representing a 13.86% increase compared to ¥756,709,758.78 in 2023[22]. - The net profit attributable to shareholders for 2024 was -¥37,690,897.81, a 60.06% improvement from -¥94,365,092.81 in 2023[22]. - The company reported a net profit margin of 12%, up from 10% in the previous quarter[9]. - The medical dental service sector contributed ¥773,486,896.92, accounting for 89.78% of total revenue, with a growth of 13.94% compared to the previous year[56]. - The electrical switch industry generated ¥86,032,001.18, making up 9.98% of total revenue, with a year-on-year increase of 13.55%[56]. - Revenue from the dental medical industry reached ¥773,486,896.92, an increase of 13.94% year-over-year, with a gross margin of 50.10%[58]. - Domestic sales amounted to ¥861,568,412.49, up 13.86% year-over-year, with a gross margin of 48.33%[58]. User Growth and Market Expansion - User data indicates a growth in active users, reaching 500,000, which is a 20% increase compared to the previous year[15]. - The company plans to expand its market presence by entering three new provinces in the upcoming year, targeting a 25% increase in market share[15]. - Market expansion efforts have led to a 25% increase in presence across three new regions[6]. Product Development and Innovation - New product development includes the launch of a cutting-edge dental imaging system, expected to enhance service efficiency by 30%[15]. - The company is focused on developing new products and expanding its market presence in the electrical industry, aligning with national manufacturing strategies[34]. - The company is committed to digital transformation and innovation in the dental medical industry, aiming to improve service quality and patient experience[33]. - The company has allocated 100 million yuan for research and development in innovative medical technologies over the next two years[15]. - The company has received 2 new invention patents and 3 utility model patents in 2024, further strengthening its intellectual property portfolio[45]. Financial Management and Governance - The board has decided not to distribute cash dividends for this fiscal year, focusing on reinvestment for growth[5]. - The company emphasizes its commitment to corporate governance and transparency, ensuring all financial reports are audited and accurate[4]. - The company has established a complete and independent financial accounting department, ensuring no shared bank accounts with related parties[119]. - The company has a governance structure that complies with the requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange[111]. Risk Management - The company is actively monitoring potential risks related to market fluctuations and regulatory changes, with a detailed risk management plan in place[4]. - The company emphasizes the importance of strict risk control and scientific investment decisions to ensure stable development in the future[107]. Employee and Management Structure - The total number of employees at the end of the reporting period was 1,714, with 1,752 employees receiving salaries during the period[148]. - The company has a diverse management team with backgrounds in finance, law, and clinical medicine[125][126]. - The company has implemented a strict compensation management system, linking employee salaries to company performance[150]. Social Responsibility and Community Engagement - The company actively engages in social responsibility initiatives, focusing on product safety, environmental protection, and employee rights[162]. - The company participates in community health initiatives, such as free medical consultations for underprivileged women during International Women's Day[163]. Legal and Compliance Matters - The company received a civil judgment on September 27, 2024, which dismissed all litigation requests from Beijing Shoutuo Ronghui Investment Co., Ltd.[106]. - The company is currently involved in a litigation case with Jin Haitang Asset Management Co., with a disputed amount of ¥362.30 million, which has been classified as a contingent liability[193]. - The company received an unqualified audit report for the 2024 financial statements, with an emphasis on the ongoing litigation regarding control disputes[184].

Financial Performance - The company's revenue for Q1 2025 was ¥142,937,780.75, a decrease of 12.58% compared to ¥163,503,563.10 in the same period last year[5] - The net loss attributable to shareholders was ¥12,214,580.55, representing a 167.13% increase in losses from ¥4,572,538.15 year-over-year[5] - Net profit for the period was a loss of ¥18,003,655.24, compared to a loss of ¥7,025,281.32 in the previous period, representing an increase in losses of approximately 156.5%[19] - Total operating revenue decreased to ¥142,937,780.75 from ¥163,503,563.10, a decline of approximately 12.5% year-over-year[17] - Total operating costs reduced to ¥167,162,234.16 from ¥179,781,974.53, a decrease of about 7.1% year-over-year[17] - Other comprehensive income after tax was a loss of ¥3,764,533.94, compared to a gain of ¥900,341.54 in the previous period[19] - Total comprehensive income for the period was a loss of ¥21,768,189.18, compared to a loss of ¥6,124,939.78 in the previous period[19] Cash Flow - The net cash flow from operating activities was negative at ¥17,184,700.35, a decline of 43.83% compared to the previous year's figure of ¥-11,948,253.48[5] - Cash flow from operating activities showed a net outflow of ¥17,184,700.35, worsening from a net outflow of ¥11,948,253.48 in the prior period[19] - Investment activities cash outflow totaled 278,026.75, resulting in a net cash flow from investment activities of -278,026.75[20] - Financing activities cash outflow amounted to 4,008,248.21, leading to a net cash flow from financing activities of -4,008,248.21[20] - The net increase in cash and cash equivalents was -21,470,870.05, with an ending balance of 125,099,938.62[20] - The beginning balance of cash and cash equivalents was 146,570,808.67[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,457,181,348.51, down 2.69% from ¥1,497,483,643.54 at the end of the previous year[5] - Current assets decreased from CNY 296,422,510.85 to CNY 271,723,944.04, a reduction of about 8.3%[13] - Non-current assets decreased from CNY 1,201,061,132.69 to CNY 1,185,457,404.47, indicating a decline of approximately 1.3%[14] - Total liabilities decreased from CNY 1,054,436,349.33 to CNY 1,035,902,243.48, a decrease of about 1.4%[14] - The company's cash and cash equivalents decreased from CNY 147,693,180.87 to CNY 126,548,983.48, a decline of approximately 14.3%[13] - Accounts receivable decreased from CNY 39,169,433.88 to CNY 32,094,965.57, reflecting a decrease of about 18.0%[13] - Inventory decreased slightly from CNY 50,753,348.55 to CNY 49,266,292.91, a reduction of approximately 2.9%[13] - The company's short-term borrowings remained relatively stable, decreasing slightly from CNY 191,588,304.03 to CNY 191,458,466.67[14] - The total equity attributable to shareholders of the parent company decreased to ¥382,056,059.67 from ¥398,035,174.16, a decline of approximately 4.0%[18] - The total liabilities and equity amounted to ¥1,457,181,348.51, down from ¥1,497,483,643.54, reflecting a decrease of about 2.7%[18] Research and Development - Research and development expenses increased by ¥2,600,000, marking a 163% rise compared to the same period last year[8] - Research and development expenses increased significantly to ¥4,192,860.44 from ¥1,594,263.46, marking a rise of about 162.5% year-over-year[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 54,029, with the largest shareholder holding 23.81% of the shares[10] Government Support - The company received government subsidies amounting to ¥328,966.43, which positively impacted other income[7] Other Information - The company has not audited its first-quarter report[21] - The financial report for the year 2025 will first apply new accounting standards[22]

皓宸医疗科技股份有限公司 2024 年度 内部控制审计报告 D 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://accm6.gov.cn） 进行变 内部控制审计报告 众会字(2025)第 02983 号 皓宸医疗科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了皓 宸医疗科技股份有限公司(以下简称"皓宸医疗")2024年12月31日的财务报告内部控制 的有效性。 我们认为,皓宸医疗于 2024年12月 31 日按照《企业内部控制基本规范》和相关规定 在所有重大方面保持了有效的财务报告内部控制。 ZHONGHUA 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》的规定,建立健全和有效 实施内部控制,并评价其有效性是皓宸医疗董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变 化可能导致内部控制变 ...

您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行整 " . . . . 皓宸医疗科技股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来情况 的专项说明 众会字(2025)第 02985 号 皓宸医疗科技股份有限公司全体股东: 我们接受委托,依据《中国注册会计师执业准则》审计了皓宸医疗科技股份有限公司(以下简称"皓 宸医疗")2024年度的财务报表,包括 2024年 12月 31 日的合并及公司资产负债表,2024年度的合并 及公司利润表、合并及公司现金流量表、合并所有者权益变动表及公司所有者权益变动表以及财务报 表附注,并于 2025年 4 月 25 日出具了众会字(2025)第 02981 号《审计报告》。 皓宸医疗科技股份有限公司 2024 年度非经营性资金占用及其他 关联资金往来情况的专项说明 根据中国证券监督管理委员会《上市公司监管指引第 8 号 -- 上市公司资金往来、对外担保的监 管要求》的要求以及参照深圳证券交易所《深圳证券交易所上市公司自律监管指南第1号 -- 业务办 理》规定的非经营性资金占用及其他关联资金往来情况汇总表 ...

皓宸医疗科技股份有限公司 2024 年度 营业收入扣除情况专项审核报告 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行额 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mo.f.gov.cn）"进行额2 0 ZHONO 专项审核报告 众会字(2025) 第 02984 号 皓宸医疗科技股份有限公司全体股东: 我们接受委托,审计了皓宸医疗科技股份有限公司(以下简称"皓宸医疗")2024年度 的财务报表,包括2024年12月31日的合并及公司资产负债表,2024年度的合并及公司利 润表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注,并于 2025年4月25日出具了众会字(2025)第 02981 号审计报告。同时,我们审核了后附的皓 宸医疗 2024 年度营业收入扣除情况表。 一、管理层的责任 皓宸医疗管理层的责任是提供真实、合法、完整的相关资料,按照《深圳证券交易所上 市规则》以及《深圳证券交易所上市公司自律监管指南第1号 -- 业务办理》的要求编制营 业收入扣除情况表,并保证其内容真实、准确、完整 ...

皓宸医疗科技股份有限公司 2024 年度 财务报表及审计报告 皓宸医疗科技股份有限公司全体股东: 一、审计意见 我们审计了皓宸医疗科技股份有限公司（以下简称"皓宸医疗"、"公司"》财务报表,包括 2024 年 12 月 31 日的合并及公司资产负债表,2024年度的合并及公司利润表、合并及公司现金流量表、合并及公司 股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了皓宸医疗 2024 年 12月 31 日的合并及公司财务状况以及 2024 年度的合并及公司经营成果和现金流量。 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://www.blog.cn） 班托 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://zc.mof.gov.cn） 我打 【 ALL 2017 目 录 | 内容 | 页码 | | --- | --- | | 审计报告 | | | 2024 年 12 月 31 日合并资产负债表 | 1-2 | | 2024年12月 31 日公司资产负债表 | 3-4 | | 2024 年度合并利润表 | ...

关于对皓宸医疗科技股份有限公司 2024年度财务报表发表强调事项段 无保留意见的专项说明 众会字(2025) 第02982号 皓宸医疗科技股份有限公司全体股东: 关于对皓宸医疗科技股份有限公司 2024 年度财务报表发表带有强调事项段 无保留意见的专项说明 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mo.gov.cn）"进行企 发现" and and the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the station of : ZHONGHUA 我们接受委托,审计了皓宸医疗科技股份有限公司(以下简称"皓宸医疗")的财务报表 ,包括2024年12月31日的合并及公司资产负债表,2024年度的合并及公司利润表、股东权益 变动表和现金流量表以及相关财务报表附注,并于2025年4月25日出具了众会字(2025)第 02981号带有 ...

4月14日，皓宸医疗今日收盘2.61元，上涨3.16%，最新市净率4.90，总市值21.92亿元。 股东方面，截至2024年9月30日，皓宸医疗股东户数44932户，较上次增加3565户，户均持股市值35.28 万元，户均持股数量2.76万股。 皓宸医疗科技股份有限公司主要从事口腔医疗服务以及永磁开关及高低压开关成套设备产品的研发、生 产和销售。其主要产品有医疗口腔服务、实业开关产品、征信大数据软件服务。 最新一期业绩显示，2024年三季报，公司实现营业收入6.35亿元，同比21.27%；净利润1349.67万元， 同比-17.31%，销售毛利率47.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)9皓宸医疗-22.56-23.234.9021.92亿行业平均 46.7942.233.41144.65亿行业中值47.8135.902.5448.88亿1普瑞眼科-191.8123.972.9064.23亿2何氏眼 科-150.9446.281.5229.41亿3迪安诊断-96.3529.011.2689.18亿4光正眼科-90.07214.007.2619.81亿5南华生 物-81.46-107 ...